Deferred Tax Assets, Operating Loss Carryforwards of Sunshine Biopharma Inc. from 31 Dec 2014 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Sunshine Biopharma Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2014 to 31 Dec 2024.
  • Sunshine Biopharma Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $6,460,638, a 22% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Sunshine Biopharma Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $6,460,638 +$1,182,809 +22% 31 Dec 2024 10-K 01 Apr 2025 2024 FY
Q4 2023 $5,277,829 +$954,804 +22% 31 Dec 2023 10-K 01 Apr 2025 2024 FY
Q4 2022 $4,323,025 -$23,717,237 -85% 31 Dec 2022 10-K 04 Apr 2023 2022 FY
Q4 2021 $28,040,262 +$12,099,180 +76% 31 Dec 2021 10-K 21 Mar 2022 2021 FY
Q4 2020 $15,941,082 +$15,702,038 +6569% 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q4 2019 $239,044 -$149,054 -38% 31 Dec 2019 10-K 30 Mar 2021 2020 FY
Q4 2018 $388,098 -$3,616,101 -90% 31 Dec 2018 10-K 01 May 2020 2019 FY
Q4 2017 $4,004,199 +$396,879 +11% 31 Dec 2017 10-K 12 Apr 2019 2018 FY
Q4 2016 $3,607,320 -$813,728 -18% 31 Dec 2016 10-K 02 Apr 2018 2017 FY
Q2 2016 $3,774,644 30 Jun 2016 10-Q 16 Aug 2016 2016 Q2
Q1 2016 $3,626,029 31 Mar 2016 10-Q 09 May 2016 2016 Q1
Q4 2015 $4,421,048 +$1,163,153 +36% 31 Dec 2015 10-Q 14 Nov 2016 2016 Q3
Q3 2015 $2,869,575 30 Sep 2015 10-Q 04 Nov 2015 2015 Q3
Q4 2014 $3,257,895 31 Dec 2014 10-Q 04 Nov 2015 2015 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.